

20 July 2020

**DEDALUS HOLDING, A COMPANY PARTICIPATED BY ARDIAN, HAS REACHED A BINDING AGREEMENT FOR THE ACQUISITION OF THE BUSINESS SOFTWARE SOLUTIONS FOR THE HEALTHCARE SECTOR OF THE US COMPANY DXC TECHNOLOGIES**

From a leading company in Continental Europe, Dedalus becomes a global operator and strengthens its leadership position in IT solutions for the healthcare sector both at European and global level by going to operate in 40 countries around the world.

The acquisition is based on the strong complementarity of the two companies that share the same product and solution development technologies.

The goal is to accelerate the digital transformation of the Healthcare ecosystem thanks to the dimensional scale that increases R&D capabilities.

Post acquisition, Dedalus will have over 5,500 people, of which about 2,000 in R&D, and will have a pro-forma turnover of over 700 million euros. Over 3 billion clinical documents each year are produced globally by professionals who use Dedalus solutions.

Florence, 21 July 2020 - The Dedalus Group, 75% owned by Ardian and operating internationally in the clinical-health software sector, announces that it has reached a binding agreement for the acquisition of the Healthcare Software Solutions business of the American DXC Technology (NYSE: DXC), one of the largest global IT services companies.

Thus was born a global operator in the field of software solutions in the hospital and diagnostic field with a presence in over 40 countries; a leadership position in the major European countries, including Germany, Italy, UK, France and Spain; an estimated total turnover of approximately 700 million euros; the largest R&D platform in the Healthcare Software sector; and a management team with international expertise gained in the most important software multinationals.

**Dedalus Italia S.p.A. con Socio Unico © Copyright 2018**

**Sede Legale:**

Via di Collodi 6/c  
50141 Firenze

**Sede di Milano:**

P.zza Santissima Trinità  
6 - 20154

**Capitale sociale:**

€ 11.634.062 i.v.  
R.E.A. Firenze 591564

**Codice fiscale, partita IVA**

e registro imprese  
05994810488



In detail, the object of the acquisition is the business, 100% owned by DXC Technology, relating to healthcare clinical software solutions for hospitals, diagnostic laboratories, general practitioners and outpatients, with a leading position in the United Kingdom, Australia, New Zealand and Spain and a significant position in the countries of Northern Europe, Latin America, Asia and Middle East and North America where DXC has always operated. The activity covers all aspects of the clinical decision-making process, facilitating the collaboration of all players in the healthcare sector around the patient in an integrated approach.

The acquisition finds its rationale in the important synergies between the two companies that will allow it to expand the leadership of Dedalus in the main European countries, extend its presence in markets not yet covered, and form a qualified team of the highest level led by the CEO by Dedalus Andrea Fiumicelli and by President Giorgio Moretti, to achieve a unique investment dimension and capacity that will allow to accelerate the digitalization of Healthcare, which is still in an initial phase of its transformation.

